Skip to main content
. Author manuscript; available in PMC: 2023 Nov 1.
Published in final edited form as: Alzheimers Dement. 2022 Feb 1;18(11):2199–2208. doi: 10.1002/alz.12519

Table 2:

Hazard Ratios for progression to a clinical diagnosis of AD for each predictor variable in bivariate survival analyses.

Hazard Ratios (95% CI) Wald X2 p-value
Demographics
Age 1.12 (1.12–1.13) 834.84 <.001
MMSE .79 (.76–.82) 185.84 <.001
Education (yrs) 1.00 (.98–1.02) .001 .97
Sex (male) 1.00 (.87–1.14) .003 .95
Medications
Anxiolytic 1.23 (.99–1.53) 3.58 .06
Antidepressant 1.73 (1.48–2.02) 45.83 <.001
Antipsychotic 1.63 (.67–3.98) 1.15 .28
Medical Conditions
Diabetes 1.25 (1.00–1.55) 3.91 .05
Hypercholesterolemia .80 (.70–.90) 12.91 <.001
Hypertension 1.06 (.94–1.20) .78 .38
Heart attack 1.21 (.65–2.29) .36 .55
Atrial Fibrillation 1.14 (.86–1.51) .79 .37
Stroke 4.53 (2.58–7.93) 27.86 <.001
TIA 1.07 (.58–1.97) .05 .82
Health Behaviours
Smoking (years) 1.00 (.99–1.00) .07 .80
Alcohol abuse (present versus absence) 1.43 (.75–2.74) 1.15 .28
Other Risk Factors
APOE4 allele (presence versus not) 3.10 (2.74–3.49) 336.54 <.001
HHS Vulnerability Disclosure